Predicine to Introduce PredicineALERTTM MRD Assay and Present Twelve Posters at AACR 2023 Conference   New research demonstrates the value of genomic and epigenomic methylation sequencing capabilities of Predicine liquid biopsy platform for biomarker discovery, treatment selection, therapy monitoring and minimal residual disease monitoring.   SILICON VALLEY, Calif., April 14, 2023 – Predicine, a global molecular...

Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays   SILICON VALLEY, Calif., Feb. 16, 2023 — Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing (NGS)...

Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Silicon Valley, Calif., Nov 10, 2022 – Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive next-generation liquid biopsy solution that provides genome-wide, genomic and epigenomic insights to capture...

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration   SILICON VALLEY, Calif., (September 20, 2022) – Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...

SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held September 9-13, 2022, in Paris, France. Predicine’s liquid biopsy portfolio includes high performing assays that provide translational insights to aid in potential cancer therapeutic strategies....

SILICON VALLEY, Calif., Aug 09, 2022 / Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine. The PredicineCARETM cell free DNA (cfDNA) assay is a targeted Next-Generation Sequencing (NGS) assay for the detection of single nucleotide variants (SNVs), insertions and deletions (Indels), DNA re-arrangements (fusions)...

SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today a nationwide expansion of its COVID-19 testing solution through the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of Predicine’s SARS-CoV-2 RT-PCR test and self-collection kit....

Predicine Liquid Biopsy Outperforms Four other Leading ctDNA NGS Tests in a Study Led by Bristol Myers Squibb SILICON VALLEY, Calif., May 13, 2022 /PRNewswire/ — Predicine, Inc., a global molecular insights company, today announced the results of a new research study that demonstrated superior performance of the PredicineATLAS™ liquid biopsy next-generation sequencing (NGS) assay compared to four...

Predicine to Attend 2022 AACR Conference in New Orleans to Highlight the Launch of PredicineBEACON™, a Novel, Tissue-agnostic, Actionable Assay for Minimal Residual Disease (MRD) Detection and the Recent Publication of Several Studies in Genitourinary (GU) Cancers PredicineBEACON™ offers ultra-sensitive detection of disease recurrence and is compatible with blood, urine- and/or tissue specimens. Urine-based MRD has...

Predicine Expands Its Footprint in the Greater Chicago Area to Better Serve Their Patients by Increasing Daily Capacity and Faster Turnaround Time SCHAUMBURG, Ill., April 11, 2022 /PRNewswire/ — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announces the grand opening of its Chicago lab in Schaumburg, IL on April 2, 2022. This lab...